Pub-2015

Articles

Title
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia
Rituximab intolerance in patients with Waldenstrom's macroglobulinaemia
MYD88 Mutations and Response to Ibrutinib in Waldenström’s Macroglobulinemia
LLF - Waldenstrom's Macroglobulinemia Facts
Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia
How I treat Waldenstrom macroglobulinemia
Survival outcomes of secondary cancers in patients with Waldenström Macroglobulinemia: An analysis of the SEER database
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia
Extramedullary Waldenström macroglobulinemia
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database
Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4(Wild-type) and CXCR4(WHIM) mutated Waldenstrom macroglobulinaemia cells